Xspray Pharma: BE study for 505(b)(2) has commenced
Redeye reiterates its Base Case of SEK 170 following today's news announcement that the study for the improved version of dasatinib has commenced. Xspray's improved version of dasatinib has been tested in humans before with good results. Thus, we see a good probability of reaching BE in the data readout from the study in Q3. In the press release, the company also mentions that the BE study for the "C"-formulation will be initiated this summer..